tiprankstipranks
Trending News
More News >
Sipai Health Technology Co., Ltd. (HK:0314)
:0314
Hong Kong Market
Advertisement

Sipai Health Technology Co., Ltd. (0314) AI Stock Analysis

Compare
1 Followers

Top Page

HK:0314

Sipai Health Technology Co., Ltd.

(0314)

Rating:47Neutral
Price Target:
HK$6.50
▲(10.54% Upside)
The overall stock score is primarily impacted by severe financial performance issues, including recurring losses and reliance on external financing. While technical analysis indicates strong market momentum, the negative valuation metrics due to ongoing losses further hinder the stock's attractiveness.

Sipai Health Technology Co., Ltd. (0314) vs. iShares MSCI Hong Kong ETF (EWH)

Sipai Health Technology Co., Ltd. Business Overview & Revenue Model

Company DescriptionSipai Health Technology Co., Ltd. (0314) is a company that operates in the healthcare technology sector. It specializes in providing innovative health solutions through its various products and services, focusing on improving patient care and optimizing health management systems. The company leverages technology to deliver advanced healthcare services and products that cater to both individual and institutional clients.
How the Company Makes MoneySipai Health Technology Co., Ltd. generates revenue through the development and sale of healthcare technology products and services. Key revenue streams include the sale of medical devices, software solutions for healthcare management, and consulting services. The company may also form strategic partnerships with hospitals, clinics, and other healthcare providers to enhance its offerings and expand its market reach. Additionally, Sipai Health Technology Co., Ltd. might earn income through licensing agreements and collaborations with other technology firms to integrate cutting-edge innovations into its product lineup.

Sipai Health Technology Co., Ltd. Financial Statement Overview

Summary
Sipai Health Technology Co., Ltd. faces significant financial challenges characterized by recurring losses and cash flow inefficiencies. Despite revenue growth in certain years, profitability remains an issue due to high operational costs. Improvements in balance sheet stability are noted, yet historical financial distress impacts overall financial health. The company's reliance on external financing to sustain operations highlights potential risks if external funding becomes constrained.
Income Statement
35
Negative
The company has demonstrated a mixed revenue trajectory with growth from 2019 to 2021, followed by a decline in 2024. Gross profit margin remains low, indicating limited profit from sales. There is consistent negative net profit margin due to significant losses, reflecting poor profitability and efficiency. Persistent negative EBIT and EBITDA margins indicate operational challenges and inefficiencies.
Balance Sheet
40
Negative
Sipai Health Technology's debt-to-equity ratio is low, indicating manageable debt levels relative to equity. However, the negative equity in earlier years signals financial instability. Recent positive equity suggests improvement, yet return on equity remains negative due to continuous net losses. The company's equity ratio has improved, enhancing balance sheet stability but still reflecting past financial distress.
Cash Flow
30
Negative
The company consistently reports negative operating cash flow, reflecting challenges in generating cash from operations. Free cash flow has shown improvement but remains negative, suggesting ongoing cash strain. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in converting income to cash. Financing activities have historically supported cash positions, but dependency on external funding poses risks.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.57B4.71B4.12B3.47B2.70B
Gross Profit366.10M399.71M334.83M276.68M186.86M
EBITDA-334.60M-189.21M-1.53B-4.45B-1.11B
Net Income-323.74M-255.77M-1.37B-3.74B-1.04B
Balance Sheet
Total Assets2.27B2.82B2.93B2.89B2.48B
Cash, Cash Equivalents and Short-Term Investments919.77M1.13B1.53B1.61B1.67B
Total Debt45.49M67.56M67.76M7.52B63.59M
Total Liabilities1.06B1.18B1.10B8.32B4.27B
Stockholders Equity1.23B1.62B1.84B-5.43B-1.80B
Cash Flow
Free Cash Flow-70.15M-139.24M-193.87M-643.33M-206.83M
Operating Cash Flow-59.45M-133.50M-182.07M-621.92M-192.12M
Investing Cash Flow-622.00K-720.81M1.03B-1.02B319.62M
Financing Cash Flow-184.06M-120.55M81.69M559.29M1.31B

Sipai Health Technology Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.88
Price Trends
50DMA
5.47
Positive
100DMA
4.95
Positive
200DMA
5.07
Positive
Market Momentum
MACD
0.08
Positive
RSI
50.55
Neutral
STOCH
21.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Positive. The current price of 5.88 is below the 20-day moving average (MA) of 6.15, above the 50-day MA of 5.47, and above the 200-day MA of 5.07, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0314.

Sipai Health Technology Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
HK$5.72B25.6911.24%1.03%11.23%20.39%
73
Outperform
HK$5.66B12.838.40%2.36%12.41%
67
Neutral
HK$14.01B45.767.40%1.06%0.67%-1.75%
60
Neutral
HK$18.32B5.55-4.00%3.32%9.92%-18.97%
55
Neutral
€5.87B-10.43%36.76%42.89%
47
Neutral
HK$4.36B-22.75%-5.07%-21.18%
41
Neutral
HK$3.82B-69.97%3.30%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0314
Sipai Health Technology Co., Ltd.
5.90
0.15
2.61%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
7.74
0.19
2.52%
HK:1931
IVD Medical Holding Limited
8.72
8.08
1262.50%
HK:1763
China Isotope & Radiation Corp.
17.88
7.72
75.98%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
32.50
3.90
13.64%
HK:9996
Peijia Medical Ltd.
8.79
6.14
231.70%

Sipai Health Technology Co., Ltd. Corporate Events

Sipai Health Technology Announces Upcoming Board Meeting for Interim Results
Aug 5, 2025

Sipai Health Technology Co., Ltd. has announced that its board of directors will hold a meeting on August 18, 2025, to approve the unaudited interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it could impact the company’s financial strategy and shareholder returns.

Sipai Health Technology Announces Change in Share Registrar
Jul 18, 2025

Sipai Health Technology Co., Ltd. has announced a change in its Hong Kong branch share registrar and transfer office, effective August 1, 2025, to Tricor Investor Services Limited. This move is significant for the company’s administrative operations and may impact shareholders who need to adjust to the new registrar for share-related transactions.

Sipai Health Technology Invests in Wealth Management Product for Treasury Optimization
Jun 26, 2025

Sipai Health Technology Co., Ltd. has entered into a subscription agreement with JPM to invest in a wealth management product, specifically a Callable Fixed Coupon Note, with a principal amount of US$30 million and an expected annual return rate of 4.58%. This investment is part of the company’s treasury management strategy to maximize returns on surplus cash, offering better yields and flexibility compared to other products, and is considered beneficial for the company and its shareholders.

Sipai Health Redeems Wealth Management Products for US$23.7 Million
Jun 25, 2025

Sipai Health Technology Co., Ltd. recently redeemed wealth management products from HSBC amounting to US$23.7 million, with an accrued interest income of approximately US$344,115.87. This transaction, classified as a discloseable transaction under the Listing Rules, will contribute to the company’s general working capital, potentially impacting its financial operations positively.

Sipai Health Technology Secures Shareholder Approval for Key AGM Resolutions
Jun 23, 2025

Sipai Health Technology Co., Ltd. announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 20, 2025, were approved by shareholders. Key resolutions included the adoption of the company’s audited financial statements, re-election of directors, re-appointment of Ernst & Young as auditors, and granting mandates to the board for issuing and repurchasing shares. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.

Sipai Health Technology Announces Equity Disposal in Subsidiaries
Jun 18, 2025

Sipai Health Technology Co., Ltd. has announced a supplemental disclosure regarding the disposal of its 51% equity interest in four non-wholly owned subsidiaries. The consideration for the disposal was determined through arm’s length negotiations, taking into account the net asset value and historical performance of the target companies, which have experienced a slight decline. The agreed consideration represents a slight discount to a slight premium over the most recent net asset value, and the directors consider it fair and reasonable, serving the interests of the company and its shareholders.

Sipai Health Technology Partners with Gallagher for Strategic Insurance Innovation
Jun 16, 2025

Sipai Health Technology Co., Ltd. has announced a strategic cooperation framework agreement with Arthur J. Gallagher (Singapore) Pte. Ltd. to jointly develop customized insurance solutions and promote innovation in the health insurance sector. This collaboration aims to integrate Sipai’s customer resources with Gallagher’s product design and reinsurance capabilities, enhancing customer service and driving product upgrades. The agreement, initially set for five years, represents a significant opportunity for both parties to leverage their strengths and achieve mutual benefits, potentially reinforcing Sipai’s market leadership.

Sipai Health Technology Announces Disposal of Subsidiary Equity Interests
Jun 6, 2025

Sipai Health Technology Co., Ltd., through its wholly-owned subsidiary Sipai Wisdom, has entered into agreements to sell its entire equity interest in four non-wholly owned subsidiaries to Shengyang Yijiachen and Shenyang Hengruisheng for RMB5,899,786. This transaction will result in the Group ceasing to hold any interest in these subsidiaries, which will no longer be included in its consolidated financial statements. The disposal is classified as a discloseable transaction under the Hong Kong Listing Rules, as it involves a percentage ratio of more than 5% but less than 25%, and does not constitute a connected transaction.

Sipai Health Technology Announces Annual General Meeting and Key Resolutions
May 29, 2025

Sipai Health Technology Co., Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025, in Shanghai. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, re-appointment of Ernst & Young as auditors, and authorizations related to share issuance. These resolutions aim to strengthen the company’s governance and financial oversight, potentially impacting its market positioning and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025